

Cover Story
Clinical
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years
- NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown
- Most Favored Nation drug pricing could put China on top
- Protecting the cure: Why the future of radiation oncology must be precision-guided
















